Client login

Search

Home / Knowledge Center /

Diagnostic Services / Almac validate Illumina TruSight® Tumor 170 Assay

Webinar

Almac validate Illumina TruSight® Tumor 170 Assay

In this webinar, Dr Leeona Galligan, VP UK Operations at Almac Diagnostic Services will discuss:

An overview on Almac Diagnostic Services
TruSight® Tumor 170 overview
TruSight® Tumor 170 Analytical Validation at Almac
Clinical Trial Framework for TruSight® Tumor 170 at Almac

For more information visit our Current Assay section.

View Resource

Diagnostic Services

Your global partner for biomarker discovery, development & commercialization.

Genomic Services

We offer a range of genomics platform and chemistry options, alongside expert data sciences support and a full sample management service.

Clinical Trial Assays

Comprehensive development, validation & delivery service for research and clinical use assays from our global clinical laboratories in USA, Europe and APAC.

Companion Diagnostics

A collaborative Companion Diagnostic partnership approach with a deep understanding of client needs. We offer CDx development, manufacture & commercialization services.

Related Resources

DNA Damage Response Deficiency Assay predicts response to treatment in ovarian cancer

DNA Damage Response Deficiency Assay predicts response to treatment in ovarian cancer

Stay up-to-date with the latest from Almac

Join our mailing list

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies